search
Back to results

Skin Protectant Textile Efficacy Study for Managing Skin Fold Conditions

Primary Purpose

Erythema, Maceration, Lesion Skin

Status
Enrolling by invitation
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
DriGo Skin Protectant Textile
Sponsored by
Medline Industries
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for Erythema

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria: Individuals ≥ 18 years of age. Individuals who have evidence of one or more of the following skin fold conditions: erythema, maceration, denudation, satellite lesions, pain, itching, burning, moisture, and odor. Individuals whose treatment plan permits assessment of the skin fold condition(s) for up to six days. Exclusion Criteria: Individuals whose target area(s) are being managed with topical treatments such as antibiotics, antifungals, ointments including skin protectants, anti-itch products, anoperineal dressings or absorbent pads (eg, ARD®). Individuals with a known allergy or sensitivity to the ingredients in the SPT, such as the fabric or H2O2, as well as the tape that may be used to secure the SPT.

Sites / Locations

  • Bryan Medical Center

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

DriGo SPT

Arm Description

All participants will have the DriGo skin protectant textile applied to their skin fold condition.

Outcomes

Primary Outcome Measures

To evaluate the efficacy of SPT to improve skin fold conditions as it pertains to skin fold healing
Improvement in skin fold conditions such as erythema, maceration, denudation, satellite lesions, odor, pain, itching, and burning over five days of treatment. Improvement assessed using 1. Likert scales developed for erythema, maceration, denudation, and satellite lesions. Scoring of the target area(s) done by a third-party clinician using the Likert scale(s) and photographs taken by the PI or qualified designee on Day 0, and on Days 1, 3, and 5, during SPT changes.
To evaluate the efficacy of SPT to improve skin fold conditions as it pertains to participant assessment
Improvement in skin fold conditions such as erythema, maceration, denudation, satellite lesions, odor, pain, itching, and burning over five days of treatment. Improvement assessed using assessment of odor in the target area(s) on Day 0, and on Days 1, 3, and 5, during SPT changes, using a Likert scale. Participant assessment of discomfort (pain, itching, and burning) assessment using a VAS on Day 0, and on Days 1, 3, and 5, during SPT changes. Participants will also be asked to identify the most prominent type of discomfort in the skin fold: pain, itching, or burning.

Secondary Outcome Measures

To gather PI or qualified designee's assessment of moisture control in the target areas
PI or qualified designee survey response for moisture in the target area(s) on Day 0, and on Days 1, 3, and 5, during SPT changes, using a Likert scale (5-scale likert ranging from absent to large).
To assess HCP feedback on the SPT
HCP survey responses on Day 5 regarding feedback about the SPT, using a VAS (0-100 scale; 0 being strongly disagree, 100 being strongly agree)
To assess the overall participant experience with the SPT
Participant responses on Day 5 regarding their experience with the SPT, using a VAS (0-100 scale; 0 being no discomfort, 100 being intense discomfort)

Full Information

First Posted
February 10, 2023
Last Updated
April 11, 2023
Sponsor
Medline Industries
search

1. Study Identification

Unique Protocol Identification Number
NCT05742347
Brief Title
Skin Protectant Textile Efficacy Study for Managing Skin Fold Conditions
Official Title
Efficacy of a Skin Protectant Textile for the Management of Skin Fold Conditions
Study Type
Interventional

2. Study Status

Record Verification Date
April 2023
Overall Recruitment Status
Enrolling by invitation
Study Start Date
July 1, 2022 (Actual)
Primary Completion Date
December 31, 2023 (Anticipated)
Study Completion Date
December 31, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Medline Industries

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Product Manufactured in and Exported from the U.S.
Yes
Data Monitoring Committee
No

5. Study Description

Brief Summary
This study will evaluate the efficacy of the DriGo skin protectant textile (SPT) to manage erythema, maceration, denudation, satellite lesions, pain, itching, burning, moisture, and odor associated with skin folds (henceforth together referred to as "skin fold conditions"). Participants will be patients with skin fold conditions, which will be treated with the SPT. Healthcare providers will apply the SPT to the participants' target areas. An independent licensed clinician with experience in identifying and treating skin fold conditions, will use photographs of the skin folds and other skin-on-skin contact areas (henceforth referred to as "target area[s]") to assess the status of erythema, maceration, denudation, and satellite lesions in the target areas when the SPT is first applied (Day 0), and on Days 1, 3, and 5, during SPT changes. The Principal Investigator (PI) or qualified designee will take photographs of the target areas and assess moisture and odor in these areas. Participants will provide their impressions of pain, itching and burning in the target area(s) on the same days as the skin fold condition photography. In addition, the study will include feedback from the Health Care Providers (HCPs) about the SPT and overall experience of the participants with the SPT.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Erythema, Maceration, Lesion Skin, Skin Folds

7. Study Design

Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
80 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
DriGo SPT
Arm Type
Experimental
Arm Description
All participants will have the DriGo skin protectant textile applied to their skin fold condition.
Intervention Type
Device
Intervention Name(s)
DriGo Skin Protectant Textile
Intervention Description
All participants in this study will have the DriGo skin protectant textile applied to their skin fold condition. Erythema, denudation, maceration, odor, and moisture will be assessed following application of the SPT.
Primary Outcome Measure Information:
Title
To evaluate the efficacy of SPT to improve skin fold conditions as it pertains to skin fold healing
Description
Improvement in skin fold conditions such as erythema, maceration, denudation, satellite lesions, odor, pain, itching, and burning over five days of treatment. Improvement assessed using 1. Likert scales developed for erythema, maceration, denudation, and satellite lesions. Scoring of the target area(s) done by a third-party clinician using the Likert scale(s) and photographs taken by the PI or qualified designee on Day 0, and on Days 1, 3, and 5, during SPT changes.
Time Frame
5 days
Title
To evaluate the efficacy of SPT to improve skin fold conditions as it pertains to participant assessment
Description
Improvement in skin fold conditions such as erythema, maceration, denudation, satellite lesions, odor, pain, itching, and burning over five days of treatment. Improvement assessed using assessment of odor in the target area(s) on Day 0, and on Days 1, 3, and 5, during SPT changes, using a Likert scale. Participant assessment of discomfort (pain, itching, and burning) assessment using a VAS on Day 0, and on Days 1, 3, and 5, during SPT changes. Participants will also be asked to identify the most prominent type of discomfort in the skin fold: pain, itching, or burning.
Time Frame
5 days
Secondary Outcome Measure Information:
Title
To gather PI or qualified designee's assessment of moisture control in the target areas
Description
PI or qualified designee survey response for moisture in the target area(s) on Day 0, and on Days 1, 3, and 5, during SPT changes, using a Likert scale (5-scale likert ranging from absent to large).
Time Frame
5 days
Title
To assess HCP feedback on the SPT
Description
HCP survey responses on Day 5 regarding feedback about the SPT, using a VAS (0-100 scale; 0 being strongly disagree, 100 being strongly agree)
Time Frame
5 days
Title
To assess the overall participant experience with the SPT
Description
Participant responses on Day 5 regarding their experience with the SPT, using a VAS (0-100 scale; 0 being no discomfort, 100 being intense discomfort)
Time Frame
5 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Individuals ≥ 18 years of age. Individuals who have evidence of one or more of the following skin fold conditions: erythema, maceration, denudation, satellite lesions, pain, itching, burning, moisture, and odor. Individuals whose treatment plan permits assessment of the skin fold condition(s) for up to six days. Exclusion Criteria: Individuals whose target area(s) are being managed with topical treatments such as antibiotics, antifungals, ointments including skin protectants, anti-itch products, anoperineal dressings or absorbent pads (eg, ARD®). Individuals with a known allergy or sensitivity to the ingredients in the SPT, such as the fabric or H2O2, as well as the tape that may be used to secure the SPT.
Facility Information:
Facility Name
Bryan Medical Center
City
Lincoln
State/Province
Nebraska
ZIP/Postal Code
68506
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Skin Protectant Textile Efficacy Study for Managing Skin Fold Conditions

We'll reach out to this number within 24 hrs